{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:01:32Z","timestamp":1778731292021,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We performed a retrospective analysis to investigate dynamic peri-hematopoietic stem cell transplantation (HSCT) minimal\/measurable residual disease (MRD) on outcomes in patients with T-cell acute lymphoblastic leukemia (T-ALL). A total of 271 patients were enrolled and classified into three groups: unchanged negative MRD pre- and post-HSCT group (group A), post-MRD non-increase group (group B), and post-MRD increase group (group C). The patients in group B and group C experienced a higher cumulative incidence of relapse (CIR) (42% <jats:italic>vs.<\/jats:italic> 71% <jats:italic>vs.<\/jats:italic> 16%, <jats:italic>P<\/jats:italic>&lt;0.001) and lower leukemia-free survival (LFS) (46% <jats:italic>vs.<\/jats:italic> 21% <jats:italic>vs.<\/jats:italic> 70%, <jats:italic>P<\/jats:italic>&lt;0.001) and overall survival (OS) (50% <jats:italic>vs.<\/jats:italic> 28% <jats:italic>vs.<\/jats:italic> 72%, <jats:italic>P<\/jats:italic>&lt;0.001) than in group A, but there was no significant difference in non-relapse mortality (NRM) among three groups (14% <jats:italic>vs.<\/jats:italic> 12% <jats:italic>vs.<\/jats:italic> 8%, <jats:italic>P<\/jats:italic>=0.752). Multivariate analysis showed that dynamic peri-HSCT MRD was associated with CIR (HR=2.392, 95% CI, 1.816\u20133.151, <jats:italic>P<\/jats:italic>&lt;0.001), LFS (HR=1.964, 95% CI, 1.546\u20132.496, <jats:italic>P<\/jats:italic>&lt;0.001) and OS (HR=1.731, 95% CI, 1.348\u20132.222, <jats:italic>P<\/jats:italic>&lt;0.001). We also established a risk scoring system based on dynamic peri-HSCT MRD combined with remission status pre-HSCT and onset of chronic graft-<jats:italic>versus<\/jats:italic>-host disease (GVHD). This risk scoring system could better distinguish CIR (c=0.730) than that for pre-HSCT MRD (c=0.562), post-HSCT MRD (c=0.616) and pre- and post-MRD dynamics (c=0.648). Our results confirm the outcome predictive value of dynamic peri-HSCT MRD either alone or in combination with other variables for patients with T-ALL.<\/jats:p>","DOI":"10.1007\/s11596-021-2390-6","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T05:02:19Z","timestamp":1624942939000},"page":"443-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"41","author":[{"given":"Zhi-dong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-qian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-fei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-jun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"issue":"14","key":"2390_CR1","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","volume":"22","author":"Y Wang","year":"2016","unstructured":"Wang Y, Liu QF, Xu LP, et al.Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. Clin Cancer Res, 2016,22(14):3467\u20133476","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2390_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ajh.25417","volume":"94","author":"XS Zhao","year":"2019","unstructured":"Zhao XS, Liu YR, Xu LP, et al.Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. Am J Hematol, 2019,94(4):512\u2013521","journal-title":"Am J Hematol"},{"issue":"4","key":"2390_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","volume":"16","author":"CH Pui","year":"2015","unstructured":"Pui CH, Pei D, Coustan-Smith E, et al.Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol, 2015,16(4):465\u2013474","journal-title":"Lancet Oncol"},{"issue":"6","key":"2390_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/14737140.2020.1766973","volume":"20","author":"YQ Sun","year":"2020","unstructured":"Sun YQ, Li SQ, Zhao XS,et al. Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene. Expert Rev Anticancer Ther, 2020,20(6):453\u2013564","journal-title":"Expert Rev Anticancer Ther"},{"key":"2390_CR5","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3389\/fimmu.2019.02516","volume":"10","author":"YJ Chang","year":"2019","unstructured":"Chang YJ, Zhao XY, Huang XJ. Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. Front Immunol, 2019,10:2516","journal-title":"Front Immunol"},{"issue":"15","key":"2390_CR6","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, et al.Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 2019,133(15):1652\u20131663","journal-title":"Blood"},{"issue":"6","key":"2390_CR7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41375-018-0307-6","volume":"33","author":"S Modvig","year":"2019","unstructured":"Modvig S, Madsen HO, Siitonen SM, et al.Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia. Leukemia, 2019,33(6):1324\u20131336","journal-title":"Leukemia"},{"issue":"10230","key":"2390_CR8","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet, 2020,395(10230):1146\u20131162","journal-title":"Lancet"},{"issue":"1","key":"2390_CR9","doi-asserted-by":"publisher","first-page":"e28719","DOI":"10.1002\/pbc.28719","volume":"68","author":"MA Burns","year":"2021","unstructured":"Burns MA, Place AE, Stevenson KE, et al.Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer, 2021,68(1):e28719","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2390_CR10","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1080\/10428194.2019.1597270","volume":"60","author":"M Xu","year":"2019","unstructured":"Xu M, Liu H, Liu Y, et al.Gene mutations and pretransplant minimal residual disease predict risk of relapse in adult patients after allogeneic hematopoietic stem-cell transplantation for T cell acute lymphoblastic leukemia. Leuk Lymphoma, 2019,60(11):2744\u20132753","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2390_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","volume":"33","author":"P Bader","year":"2015","unstructured":"Bader P, Kreyenberg H, von Stackelberg A, et al.Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol, 2015,33(11):1275\u20131284","journal-title":"J Clin Oncol"},{"issue":"21","key":"2390_CR12","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","volume":"3","author":"P Bader","year":"2019","unstructured":"Bader P, Salzmann-Manrique E, Balduzzi A, et al.More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv, 2019,3(21):3393\u20133405","journal-title":"Blood Adv"},{"issue":"8","key":"2390_CR13","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2015.59","volume":"29","author":"C Eckert","year":"2015","unstructured":"Eckert C, Hagedorn N, Sramkova L, et al.Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia, 2015,29(8):1648\u20131655","journal-title":"Leukemia"},{"issue":"6","key":"2390_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/ijlh.12711","volume":"39","author":"X Zhao","year":"2017","unstructured":"Zhao X, Hong Y, Qin Y, et al.The clinical significance of monitoring the expression of the SIL-TAL1 fusion gene in T-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Int J Lab Hematol, 2017,39(6):613\u2013619","journal-title":"Int J Lab Hematol"},{"key":"2390_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fonc.2020.00320","volume":"10","author":"SQ Li","year":"2020","unstructured":"Li SQ, Fan QZ, Xu LP, et al.Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. Front Oncol, 2020,10:320","journal-title":"Front Oncol"},{"issue":"1","key":"2390_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/cyto.b.21840","volume":"98","author":"XY Wang","year":"2020","unstructured":"Wang XY, Fan QZ, Xu LP, et al.The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry B Clin Cytom, 2020,98(1):75\u201387","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2390_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-020-00860-y","volume":"13","author":"YJ Chang","year":"2020","unstructured":"Chang YJ, Wang Y, Xu LP, et al.Haploidentical donor is preferred over matched sibling donor for pretransplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol, 2020,13(1):27","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2390_CR18","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","volume":"20","author":"DT Teachey","year":"2019","unstructured":"Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol, 2019,20(3):e142\u2013e54","journal-title":"Lancet Oncol"},{"issue":"10","key":"2390_CR19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/CM9.0000000000001402","volume":"134","author":"LQ Cao","year":"2021","unstructured":"Cao LQ, Zhou Y, Liu YR, et al.A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation. Chin Med J (Engl), 2021,134(10):1199\u20131208","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"2390_CR20","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bjh.15086","volume":"180","author":"F Lovisa","year":"2018","unstructured":"Lovisa F, Zecca M, Rossi B, et al.Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br J Haematol, 2018,180(5):680\u2013693","journal-title":"Br J Haematol"},{"issue":"2","key":"2390_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00277-011-1285-1","volume":"91","author":"XS Zhao","year":"2012","unstructured":"Zhao XS, Liu YR, Zhu HH, et al.Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol, 2012,91(2):183\u2013192","journal-title":"Ann Hematol"},{"issue":"2","key":"2390_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41375-019-0598-2","volume":"34","author":"P Quist-Paulsen","year":"2020","unstructured":"Quist-Paulsen P, Toft N, Heyman M, et al.T-cell acute lymphoblastic leukemia in patients 1\u201345 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia, 2020,34(2):347\u2013357","journal-title":"Leukemia"},{"key":"2390_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fonc.2020.00577","volume":"10","author":"PR Tembhare","year":"2020","unstructured":"Tembhare PR, Narula G, Khanka T, et al.Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients. Front Oncol, 2020,10:577","journal-title":"Front Oncol"},{"issue":"1","key":"2390_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/bmt.2016.194","volume":"52","author":"JE Brammer","year":"2017","unstructured":"Brammer JE, Saliba RM, Jorgensen JL, et al.Multicenter analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant, 2017,52(1):20\u201327","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2390_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.13142","volume":"168","author":"R Sutton","year":"2015","unstructured":"Sutton R, Shaw PJ, Venn NC, et al.Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol, 2015,168(3):395\u2013404","journal-title":"Br J Haematol"},{"issue":"4","key":"2390_CR26","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1182\/bloodadvances.2018027003","volume":"3","author":"M Yeshurun","year":"2019","unstructured":"Yeshurun M, Weisdorf D, Rowe JM, et al.The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv, 2019,3(4):670\u2013680","journal-title":"Blood Adv"},{"issue":"5","key":"2390_CR27","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/annonc\/mds615","volume":"24","author":"TH Terwey","year":"2013","unstructured":"Terwey TH, Le Duc TM, Hemmati PG, et al.NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol, 2013,24(5):1363\u20131370","journal-title":"Ann Oncol"},{"issue":"5","key":"2390_CR28","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.coi.2009.07.016","volume":"21","author":"JJ van Rood","year":"2009","unstructured":"van Rood JJ, Oudshoorn M. When selecting an HLA mismatched stem cell donor consider donor immune status. Curr Opin Immunol, 2009,21(5):538\u2013543","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"2390_CR29","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1182\/blood-2011-11-354563","volume":"119","author":"KK Ballen","year":"2012","unstructured":"Ballen KK, Koreth J, Chen YB, et al.Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood, 2012,119(9):1972\u20131980","journal-title":"Blood"},{"issue":"2","key":"2390_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbmt.2008.11.025","volume":"15","author":"XJ Huang","year":"2009","unstructured":"Huang XJ, Liu DH, Liu KY, et al.Treatment of acute leukemia with unmanipulated HLA-mismatched\/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant, 2009,15(2):257\u2013265","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2390_CR31","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1200\/JCO.2015.63.8817","volume":"34","author":"YJ Chang","year":"2016","unstructured":"Chang YJ, Xu LP, Wang Y, et al.Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. J Clin Oncol, 2016,34(16):1855\u20131863","journal-title":"J Clin Oncol"},{"issue":"29","key":"2390_CR32","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1200\/JCO.20.00150","volume":"38","author":"YJ Chang","year":"2020","unstructured":"Chang YJ, Wu DP, Lai YR, et al.Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. J Clin Oncol, 2020,38(29):3367\u20133376","journal-title":"J Clin Oncol"},{"issue":"4","key":"2390_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.bbmt.2014.12.031","volume":"21","author":"HM Shulman","year":"2015","unstructured":"Shulman HM, Cardona DM, Greenson JK, et al.NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant, 2015,21(4):589\u2013603","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2390_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"International CLLIPIwg","year":"2016","unstructured":"International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol, 2016,17(6):779\u2013790","journal-title":"Lancet Oncol"},{"issue":"5","key":"2390_CR35","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41423-020-00597-1","volume":"18","author":"H Guo","year":"2021","unstructured":"Guo H, Chang YJ, Hong Y, et al.Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cell Mol Immunol, 2021,18(5):1172\u20131185","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"2390_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41571-018-0040-0","volume":"15","author":"RB Walter","year":"2018","unstructured":"Walter RB, Appelbaum FR. Next-generation sequencing for measuring minimal residual disease in AML. Nat Rev Clin Oncol, 2018,15(8):473\u2013474","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2390_CR37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41409-018-0300-8","volume":"54","author":"J Liu","year":"2019","unstructured":"Liu J, Ma R, Liu YR, et al.The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplant, 2019,54(4):567\u2013577","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2390_CR38","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/leu.2016.46","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Othus M, Araki D, et al.Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia, 2016,30(7):1456\u20131464","journal-title":"Leukemia"},{"issue":"17","key":"2390_CR39","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1182\/blood.2019003191","volume":"135","author":"A Enshaei","year":"2020","unstructured":"Enshaei A, O\u2019Connor D, Bartram J, et al.A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood, 2020,135(17):1438\u20131446","journal-title":"Blood"},{"issue":"5","key":"2390_CR40","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjh.16107","volume":"190","author":"M Gabelli","year":"2020","unstructured":"Gabelli M, Veys P, Chiesa R. Current status of umbilical cord blood transplantation in children. Br J Haematol, 2020,190(5):650\u2013683","journal-title":"Br J Haematol"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-021-2390-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-021-2390-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-021-2390-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T17:18:05Z","timestamp":1626023885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-021-2390-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["2390"],"URL":"https:\/\/doi.org\/10.1007\/s11596-021-2390-6","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"31 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}}]}}